{
    "id": "dbpedia_4642_0",
    "rank": 64,
    "data": {
        "url": "https://aacrjournals.org/cancerres/article/64/3/1130/512154/Role-of-Immature-Myeloid-Gr-1-Cells-in-the",
        "read_more_link": "",
        "language": "en",
        "title": "Role of Immature Myeloid Gr-1+ Cells in the Development of Antitumor Immunity",
        "top_image": "https://aacrjournals.org/UI/app/svg/umbrella/logo.svg",
        "meta_img": "https://aacrjournals.org/UI/app/svg/umbrella/logo.svg",
        "images": [
            "https://aacr.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/umbrella-logo.svg",
            "https://aacr.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/umbrella-logo.svg",
            "https://aacr.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/cancerres/CR-title841299291.svg",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/issue/64/3/2/m_cover.gif?Expires=1726679639&Signature=jRbGxdhB9NabYY9dS9PHlNvT6KXzVbMfn76CgsU~WYUIx0X9ZIeiEM72ByDqpxzZL88nedcW7jSZ5Qor7Xh7DWIH2HKTtfCkiWA2-Zp0E9y5TTcHmW~rGGdBD48Qnw~vihC8eXDIDBO0L7VbE-cGNTwVo7sG1yKP24DlOT4SoNr8Of22u91-HMhfkAdYOxrqYnB6Ngz94Pvi3GpvOgAYdv01MOgbrQksCOq4gkThIV2Y1-5W6uCkmdjafPUw7-JnSHwRoDimpsVJgj-qvv9hb6K-4Im8VVDwqRQKihai7RrVmGn5hgdbjY2M1570ure3e-tcwN512iVi-8MbMUlGGQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660001.jpeg?Expires=1726679640&Signature=JykTefCGYjk6rsIK9bq-~O7jZWnZG0d7wB4Ulgz0UtO~KBRW-m3-12PFUIW2lfpXCsCiWf3dUueaAFM97Lw6hAPOjCt9WUZ2npmr0ewVzyZS6OvLSUOBNmRutWHmkUwg8g8dO-9SKB-RdFlhTUbeYiLQyYh0C-Mm4X9H4EEVvhTGN38kO6onXk5pUQzHOpAvFeTpmoNCY4mpykfHzA-lIFkuxhyXNQrAjbTZ8Zc~4eHgZlhHaQaB-a4Fy2dNPPT1msbh6dieBuwd74YpKcI5D5rAX2OAGHKbRSFfkksx8H5Xx8gO7hj84-6ACF1MeM5ybtpjqgwYL-26Et60Yqjlmw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660001.jpeg?Expires=1726679640&Signature=JykTefCGYjk6rsIK9bq-~O7jZWnZG0d7wB4Ulgz0UtO~KBRW-m3-12PFUIW2lfpXCsCiWf3dUueaAFM97Lw6hAPOjCt9WUZ2npmr0ewVzyZS6OvLSUOBNmRutWHmkUwg8g8dO-9SKB-RdFlhTUbeYiLQyYh0C-Mm4X9H4EEVvhTGN38kO6onXk5pUQzHOpAvFeTpmoNCY4mpykfHzA-lIFkuxhyXNQrAjbTZ8Zc~4eHgZlhHaQaB-a4Fy2dNPPT1msbh6dieBuwd74YpKcI5D5rAX2OAGHKbRSFfkksx8H5Xx8gO7hj84-6ACF1MeM5ybtpjqgwYL-26Et60Yqjlmw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660002.jpeg?Expires=1726679640&Signature=hOvbaJrKSmno98DyIIYjzcq5k7aOeMHbYOV1EbNS6mhTaXQYz0kI0E0520TbSfR1r3C3Pw7E~T4SWE2poFMm6ualhZwvNiI5cIoAMWtq1qIMS1FeMmz9qi1wLyBAFjnTMB3Fag8FnSRY4EsodSQXoP542EjXTwysoB3nOoCrAA7ppFw7zaY4UlLwkBUoCx9FBs-mQG1roVRDEdIGPwTOzggmYU9XbDM4c-JavsxypXMTzVVuF0HxvPshbVIWIFdKUVEZpeiAVGlkYBi8dxju6hTKjHeYziyEj3fD850HSssPNCkQ3gSDVbtePKezC2inKWr-F-o34BuaK~~uIwJ1Mw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660002.jpeg?Expires=1726679640&Signature=hOvbaJrKSmno98DyIIYjzcq5k7aOeMHbYOV1EbNS6mhTaXQYz0kI0E0520TbSfR1r3C3Pw7E~T4SWE2poFMm6ualhZwvNiI5cIoAMWtq1qIMS1FeMmz9qi1wLyBAFjnTMB3Fag8FnSRY4EsodSQXoP542EjXTwysoB3nOoCrAA7ppFw7zaY4UlLwkBUoCx9FBs-mQG1roVRDEdIGPwTOzggmYU9XbDM4c-JavsxypXMTzVVuF0HxvPshbVIWIFdKUVEZpeiAVGlkYBi8dxju6hTKjHeYziyEj3fD850HSssPNCkQ3gSDVbtePKezC2inKWr-F-o34BuaK~~uIwJ1Mw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660003.jpeg?Expires=1726679640&Signature=0ygBhxIoCWJCoAWavUPveMeTSVyWmTuHlWYVm2JcBBYML3wQ~-V27QnGcYRyWBN-ECoCtfpRjRa17XdoZFx1yeTNqhLWLZHjWtGumCD8tsjqVEs-9ykWiB3dLBeXuNoLidUmR58TBspzDfWwXlezP~t91~U1EQ8B6YfK2KjjCjWMmXV6XfIsSu6foaooQ~xksry21Qf3NuhylLqwsN8OelZvpx60SwtQMpCAhwQ53B14SRA8BVM2oIHtG5aH4IS47gApFre3G2j0X~hJ61IE5e09UkHOzNkLIVcx-5HbNk61R213XD1i1fE828S-psN2sNE5LS2OBnajEas65Ux8IA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660003.jpeg?Expires=1726679640&Signature=0ygBhxIoCWJCoAWavUPveMeTSVyWmTuHlWYVm2JcBBYML3wQ~-V27QnGcYRyWBN-ECoCtfpRjRa17XdoZFx1yeTNqhLWLZHjWtGumCD8tsjqVEs-9ykWiB3dLBeXuNoLidUmR58TBspzDfWwXlezP~t91~U1EQ8B6YfK2KjjCjWMmXV6XfIsSu6foaooQ~xksry21Qf3NuhylLqwsN8OelZvpx60SwtQMpCAhwQ53B14SRA8BVM2oIHtG5aH4IS47gApFre3G2j0X~hJ61IE5e09UkHOzNkLIVcx-5HbNk61R213XD1i1fE828S-psN2sNE5LS2OBnajEas65Ux8IA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660004.jpeg?Expires=1726679640&Signature=m8DY1BE5mtVpEbUoxhEUxTqDx-gTCmmnSvk34bHP5~M63~JejzRewPW4pkfJIUukD46FTMN80HMe6cfZOla42h-2hLkpzkBfD1LLNLiMLkfgFF7APNo4SD3PozVcl~61kYLskXE-iDeO05sy8tTlclUkRSikKMYeLr0AcZmcZUmyzbN0uyKQ57BRZi214ScRIyWR6z2CEMEhW5dkmdN0UIqr-~5wquxvPN3JvSKeK3k56ang4vHT13MBd6diPeaNbnaOoQ0f2VokodhLKoibATdvZvgtJXjgln~eFhfp99tbaTy-mlAc-~kZdjVDyw5b0qgy2tRcrDpFA9zoVfJ1Kg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660004.jpeg?Expires=1726679640&Signature=m8DY1BE5mtVpEbUoxhEUxTqDx-gTCmmnSvk34bHP5~M63~JejzRewPW4pkfJIUukD46FTMN80HMe6cfZOla42h-2hLkpzkBfD1LLNLiMLkfgFF7APNo4SD3PozVcl~61kYLskXE-iDeO05sy8tTlclUkRSikKMYeLr0AcZmcZUmyzbN0uyKQ57BRZi214ScRIyWR6z2CEMEhW5dkmdN0UIqr-~5wquxvPN3JvSKeK3k56ang4vHT13MBd6diPeaNbnaOoQ0f2VokodhLKoibATdvZvgtJXjgln~eFhfp99tbaTy-mlAc-~kZdjVDyw5b0qgy2tRcrDpFA9zoVfJ1Kg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660005.jpeg?Expires=1726679640&Signature=Ko4d0wn5~fMC8imvVWjvWhQ-3vwaVyevS5xvz5ck1HPqmsSZKGkKevRK92nvfzNangje8uWShdIy8zwuLZyN3q7Pgt7qpJaYATTuV3dshnR1vh9h7uRjF6cqTpSBesU9U9VMC56966c2EPFDfBIxa8HqrgYP9BMOlGjztbILRIPi81cwMiILU6C1lTiMKGNUBCVf-6SQgfp9qxv-fHSlIp8kPu4F7xsRW8QyYVslxFypNRriNdmMfZh~A8UEDxu~VwT42TRlqmrIVtAM~ZDe6rCVl1xmzqO2OX3NLByfx73N7Ps4nG2tchD84lAhX4q3e0qnpptf5GaymaXVkJYj0w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660005.jpeg?Expires=1726679640&Signature=Ko4d0wn5~fMC8imvVWjvWhQ-3vwaVyevS5xvz5ck1HPqmsSZKGkKevRK92nvfzNangje8uWShdIy8zwuLZyN3q7Pgt7qpJaYATTuV3dshnR1vh9h7uRjF6cqTpSBesU9U9VMC56966c2EPFDfBIxa8HqrgYP9BMOlGjztbILRIPi81cwMiILU6C1lTiMKGNUBCVf-6SQgfp9qxv-fHSlIp8kPu4F7xsRW8QyYVslxFypNRriNdmMfZh~A8UEDxu~VwT42TRlqmrIVtAM~ZDe6rCVl1xmzqO2OX3NLByfx73N7Ps4nG2tchD84lAhX4q3e0qnpptf5GaymaXVkJYj0w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660006.jpeg?Expires=1726679640&Signature=F1GRRnmpBFC7zAgbPg8Q~CISJYzOLzs-EL7-IbyLHZ4PxoIGf2RdnZzKYG-sFM1gxCNKZvuKGBtjuWDagt4BS71H6UhBJs2VrkcfhC9iTtmqIp0vaaVJotd72CUn8maL-6xDL2DI769YQP2~MLvDSWWyN9lGfq-JSkCbrAZ2QwoZQqchoz3fvuYbfus8rpyu~KZHQzljeY0QqHx0Qy5mNLM9zg2A7zdvZCxOYz-UOCxnp4ZNEXdthiLf2nmX~3gk9P6kwY7d86WKwj0rBNhd6tn8GWOXvnIblb7dX~SpXN1sUEoASb-XV-hqvJP-gn9RS25xWqYQsEr01TDkvOaddw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660006.jpeg?Expires=1726679640&Signature=F1GRRnmpBFC7zAgbPg8Q~CISJYzOLzs-EL7-IbyLHZ4PxoIGf2RdnZzKYG-sFM1gxCNKZvuKGBtjuWDagt4BS71H6UhBJs2VrkcfhC9iTtmqIp0vaaVJotd72CUn8maL-6xDL2DI769YQP2~MLvDSWWyN9lGfq-JSkCbrAZ2QwoZQqchoz3fvuYbfus8rpyu~KZHQzljeY0QqHx0Qy5mNLM9zg2A7zdvZCxOYz-UOCxnp4ZNEXdthiLf2nmX~3gk9P6kwY7d86WKwj0rBNhd6tn8GWOXvnIblb7dX~SpXN1sUEoASb-XV-hqvJP-gn9RS25xWqYQsEr01TDkvOaddw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660007.jpeg?Expires=1726679640&Signature=BUsyAfBf7qiJXCHz1lUyuSgymGVOlchTN4DO59vqQYq8C0S7mYcU4oKAJ5~X49XYIdBCaFkRc2tVIJRp2MnWmWSHCsxffvfPncPDxXYr9cgmznxTOr39uocCYA-rRqfhEUn9ErYSd2NEE-gVVt2NZu-mHPLsoXIusiUZU7Z49CAF0jEFTMBwCjFDrljbJRgIAS5zSNUJmrxOTMMOUr4RMUPfyrJDYzygl5pR3249e6ta~8AHL0jf2EYDdZp72BGoQRhTRtOS5RS9kuFcALu8Sfu8focs-6vrZRIzk4qv6MYQNsDXIcV4izE7nb3jmzpmcEqCUrOUQl3PDxU3R3m4cQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2112.gif?Expires=1726679640&Signature=ob1ytBldpStYXUqNpOQpOYbv5XGGi3aXCzWtPA2~flj9fODeimXeRjHjLJdcLuc9ZVK7NJHQPhBqEmWWOibjBezVuOKtZAvH6iwR6kLyLvFwmVPj3Cr4yM2T5pK8UO7RYXzH6jgSS3JpQ~6Y228Sv-wyLEZnlQoIJjRB2YCPsxjlV8MdG1COpeP0YgrzuUcUOh3IOhXYhl1x1ILrGKG3YxStalgn3WrtyNUZTcV0mVX1uqicLf-OTbKGsEnBENxUaU4oQryVklmQaAWXcHUwDtNIE71gIfOLErI5zyN7-mdXPh9xYDCq1lASO6i23hTaVW1UXMVcv5s3NYmYS9T7eQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2113.gif?Expires=1726679640&Signature=Yy3qpphTGW5EOkKSqNdKGGrOrmZQMoMXp1W35w4L7mgakBCwEKe3BMgeghYxB4Z8QfUXprD69ND18ZLWNU1vJPoxdXnfN1cmUw4hjG-VLHL4xAB5IQ~jwNql7l0yJJlTGDN3x88i3ydS0Jhcuq4BFgQ-rIuQUVkNZdHsmgvUNPeLynGbiGHFEWUJUw1fFaG2bpCD3yixAEWadhfeVPKW-Edu-4mjbwjSZQ4Dh6MorJauwsZeytZp9St3Wnp0-pYf6CJgL4c7Bnng0uuJJb820j-C~xLpfR6F9J-OPIQZ~nq9ZBaH7K6~~mo2Gj2wxVbb0Q2aZW5VwIGWQEMAOcQJGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2106.gif?Expires=1726679640&Signature=2ddD4yyvkretQXpws9REIx3C9F~RJDAvWH5hHcegcidtC2RkeniAi20aonnIrrjBYuNvDuGrrGIJ7jvlSqskZXve67ZpX~C8k8H7~3vn2HjEeLdN2qgsRMPewoyWYl3RRgtFqgY7weLadzCoMFOJt9CAzL3qyaNR95y10WzgQXAihvKOOyNXuILj3FR4QweccBUddLAcS050jXTYHvR0OGMRY9zBab1Vy3kE~GtoRTq9Kryh18kViMemCr2OitnQ4dY4zVcUM-syOGPeONRSfRovHe7ovY6f2fa2snK0N0avf~WsHN9fGci7DRmmBlzH4KxnXzc5etgVqfy1vYnFJg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660007.jpeg?Expires=1726679640&Signature=BUsyAfBf7qiJXCHz1lUyuSgymGVOlchTN4DO59vqQYq8C0S7mYcU4oKAJ5~X49XYIdBCaFkRc2tVIJRp2MnWmWSHCsxffvfPncPDxXYr9cgmznxTOr39uocCYA-rRqfhEUn9ErYSd2NEE-gVVt2NZu-mHPLsoXIusiUZU7Z49CAF0jEFTMBwCjFDrljbJRgIAS5zSNUJmrxOTMMOUr4RMUPfyrJDYzygl5pR3249e6ta~8AHL0jf2EYDdZp72BGoQRhTRtOS5RS9kuFcALu8Sfu8focs-6vrZRIzk4qv6MYQNsDXIcV4izE7nb3jmzpmcEqCUrOUQl3PDxU3R3m4cQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2112.gif?Expires=1726679640&Signature=ob1ytBldpStYXUqNpOQpOYbv5XGGi3aXCzWtPA2~flj9fODeimXeRjHjLJdcLuc9ZVK7NJHQPhBqEmWWOibjBezVuOKtZAvH6iwR6kLyLvFwmVPj3Cr4yM2T5pK8UO7RYXzH6jgSS3JpQ~6Y228Sv-wyLEZnlQoIJjRB2YCPsxjlV8MdG1COpeP0YgrzuUcUOh3IOhXYhl1x1ILrGKG3YxStalgn3WrtyNUZTcV0mVX1uqicLf-OTbKGsEnBENxUaU4oQryVklmQaAWXcHUwDtNIE71gIfOLErI5zyN7-mdXPh9xYDCq1lASO6i23hTaVW1UXMVcv5s3NYmYS9T7eQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2113.gif?Expires=1726679640&Signature=Yy3qpphTGW5EOkKSqNdKGGrOrmZQMoMXp1W35w4L7mgakBCwEKe3BMgeghYxB4Z8QfUXprD69ND18ZLWNU1vJPoxdXnfN1cmUw4hjG-VLHL4xAB5IQ~jwNql7l0yJJlTGDN3x88i3ydS0Jhcuq4BFgQ-rIuQUVkNZdHsmgvUNPeLynGbiGHFEWUJUw1fFaG2bpCD3yixAEWadhfeVPKW-Edu-4mjbwjSZQ4Dh6MorJauwsZeytZp9St3Wnp0-pYf6CJgL4c7Bnng0uuJJb820j-C~xLpfR6F9J-OPIQZ~nq9ZBaH7K6~~mo2Gj2wxVbb0Q2aZW5VwIGWQEMAOcQJGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_cjs2106.gif?Expires=1726679640&Signature=2ddD4yyvkretQXpws9REIx3C9F~RJDAvWH5hHcegcidtC2RkeniAi20aonnIrrjBYuNvDuGrrGIJ7jvlSqskZXve67ZpX~C8k8H7~3vn2HjEeLdN2qgsRMPewoyWYl3RRgtFqgY7weLadzCoMFOJt9CAzL3qyaNR95y10WzgQXAihvKOOyNXuILj3FR4QweccBUddLAcS050jXTYHvR0OGMRY9zBab1Vy3kE~GtoRTq9Kryh18kViMemCr2OitnQ4dY4zVcUM-syOGPeONRSfRovHe7ovY6f2fa2snK0N0avf~WsHN9fGci7DRmmBlzH4KxnXzc5etgVqfy1vYnFJg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660008.jpeg?Expires=1726679640&Signature=ggLdgXH5~JPxSUDhIyRBc~6AVdRhGdFsnQsfhdFzvZjnAxIRNRonv3L9UhoSK4~qyqdk2cv5i5Y8X8yZt-HkQv2OBOrfew5UDNkIft4mSRsK3aEDWzkYudfKlmjKKh1owT0D4-CX7ArafpzPqbS4wxnUGv3SI0GHWD3E0ALqctOFiWblaFiOyvPqo1Auf6bwQnNtaxtvgUS~zMYmh8I1DuUgU2Ad8Pp90DqF9tr99EfljY6a1AYd7O60AiHeUaBOz387SvTIAJi7oJig5-sdaN39KYjEskGA-CKkg8UdUVrXslC3F-~Pk~CN1vKJe8BnnhPPI3Cpc~Q2y2m5oEnv4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/aacr/content_public/journal/cancerres/64/3/10.1158_0008-5472.can-03-1715/2/m_zch0030444660008.jpeg?Expires=1726679640&Signature=ggLdgXH5~JPxSUDhIyRBc~6AVdRhGdFsnQsfhdFzvZjnAxIRNRonv3L9UhoSK4~qyqdk2cv5i5Y8X8yZt-HkQv2OBOrfew5UDNkIft4mSRsK3aEDWzkYudfKlmjKKh1owT0D4-CX7ArafpzPqbS4wxnUGv3SI0GHWD3E0ALqctOFiWblaFiOyvPqo1Auf6bwQnNtaxtvgUS~zMYmh8I1DuUgU2Ad8Pp90DqF9tr99EfljY6a1AYd7O60AiHeUaBOz387SvTIAJi7oJig5-sdaN39KYjEskGA-CKkg8UdUVrXslC3F-~Pk~CN1vKJe8BnnhPPI3Cpc~Q2y2m5oEnv4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://aacr.silverchair-cdn.com/ImageLibrary/umbrella/icons/RSS-icon-16px.png?versionId=6455",
            "https://aacr.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/images/umbrella/footer-logo.svg?versionId=6455"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Li, Qingsheng",
            "Pan, Ping-Ying",
            "Gu, Peidi",
            "Xu, Dongping",
            "Chen, Shu-Hsia",
            "Shu-Hsia",
            "Ping-Ying"
        ],
        "publish_date": "2004-02-10T00:00:00",
        "summary": "",
        "meta_description": "Abstract. One of the mechanisms by which tumor cells evade the immune system is the lack of proper antigen-presenting cells. Improvement in host immunity",
        "meta_lang": "en",
        "meta_favicon": "//aacr.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/apple-touch-icon.png",
        "meta_site_name": "American Association for Cancer Research",
        "canonical_link": "https://aacrjournals.org/cancerres/article/64/3/1130/512154/Role-of-Immature-Myeloid-Gr-1-Cells-in-the",
        "text": "The accumulation of Gr-1+CD11b+ (Mac-1) myeloid cells often is associated with a large tumor burden (16, 17, 18, 19, 20) or a state of immune suppression (21, 22, 23, 24). Although the underlying mechanism has yet to be determined in detail, several lines of evidence indicate that tumor cells actively suppress immune responses by affecting the development of DCs. It has been shown that tumor cells may secrete cytokines capable of stimulating myelopoiesis, such as GM-CSF (19) and IL-6 (14), and cytokines that inhibit DC differentiation, including vascular endothelial growth factor (12, 13), transforming growth factor β (15), and macrophage-colony stimulating factor (14). Therefore, the accumulation of Gr-1+CD11b+ myeloid cells may be the combined effect of an increase in myelopoiesis and a blockade in DC development. This represents a significant obstacle to immune-enhancing therapy for advanced cancer. Promoting immature myeloid cells and decreasing their inhibitory activity are paramount to a successful immune-enhancing therapy in a host with a large tumor burden.\n\nGr-1+ myeloid cells have been shown to be involved in the inhibition of T-lymphocyte activation in tumor-bearing animals (16, 17, 18, 19, 20, 26, 57). However, the phenotype and the associated in vivo function have not been well defined. In the present study, we found that the majority of Gr-1+ cells derived from BM and spleen of tumor-bearing mice also expressed Ly-6C and F4/80. Bulk FrII Gr-1+ and sorted FrII Gr-1+F4/80+ cells derived from tumor-bearing mice can differentiate into CD11c+/MHC class II+ and CD11c+/CD80+ DCs in vivo and in vitro, respectively. The mechanisms by which these immature myeloid cells accumulate in the tumor-bearing host and become involved in antigen presentation are under investigation currently. Thus far, the results suggest that Gr-1 cells accumulated in tumor-bearing mice are immature myeloid cells, which are not able to properly differentiate into mature DCs in tumor-bearing animals. The developmental stage of these FrII Gr-1+ or Gr-1+/F4/80+ cells needs to be clarified. Our results indicate that FrII Gr-1+F4/80+ cells derived from tumor-bearing animals may be related to early immature myeloid cells rather than monocytes because mature monocytes do not exhibit natural suppressor activity (58). The morphology of sorted Gr-1+F4/80+ cells shows characteristics consistent with myeloid cells. Furthermore, the majority of monocytes are CD43− (59), whereas the Gr-1+F4/80+ cells found among these immature myeloid cells are CD43+ (data not shown).\n\nThe depletion of F4/80+ cells from the immature myeloid cells partially restored T-cell proliferation, suggesting that these cells are involved in immune suppression. However, other cells also may be involved in the suppression of T-cell activation because the depletion of F4/80+ cells only partially restored T-cell proliferation at lower ratios (Fig. 2,C). Thus, the presence of other immature myeloid cells capable of inhibiting T-cell responses needs to be explored. We found that, after in vitro culture with GM-CSF, sorted nonadherent BM FrII Gr-1+F4/80+ cells induced a strong mixed lymphocyte reaction by allogeneic T cells, whereas no significant mixed lymphocyte reaction was observed with GM-CSF-stimulated Gr-1−F4/80− cells (Fig. 3 B). The evidence indicates that Gr-1+F4/80+ inhibitory immature myeloid cells can differentiate into DCs in vitro.\n\nThe differentiation of immature myeloid cells to mature DCs induced by gene delivery of GM-CSF has been confirmed in vivo. After therapy, a significant increase in the number of CD11c+ DCs with the mature phenotype (MHC class II+ and CD80+) was observed in CFSE-labeled FrII cells in vivo (Fig. 4, B and C). The recruitment and maturation of DC in the TIL and spleen as a result of GM-CSF gene delivery are efficient (Fig. 5). This indicates that local cytokine gene delivery can modulate the tumor environment and initiate the proper immune response. A novel subset of murine CD11c+B220+Gr-1+ plasmacytoid DCs has been identified recently, and this subset of DCs may play a central role in antiviral innate immunity (60, 61, 62). Whether the DCs present in the TIL are identical to the murine CD11c+B220+Gr-1+ plasmacytoid DCs remains to be determined.\n\nUsing an ADV/mIL-12 and anti-4–1BB agonistic antibody combination therapy, we achieved eradication and long-term remission in mice with tumors measuring 5 × 5 mm2, but the therapy was less potent in mice with tumors >9 × 9 mm2 (46, 47). The treatment of larger tumor-bearing animals with higher doses (200, 100, and 50 μg) of anti-4–1BB did not statistically improve their survival rate.1 However, combination therapy with GM-CSF, IL-12, and 4–1BB costimulation improved the therapeutic efficacy dramatically in mice with large tumor burdens compared with the effect observed in those animals receiving only IL-12 and 4–1BB in this study. Furthermore, the combination therapy induced a stronger antitumor response. The enhanced efficacy and stronger antitumor responses can be attributed to several mechanisms. GM-CSF may promote the differentiation of immature myeloid cells into DCs (Fig. 4, B and C), thus contributing to the innate antitumor immunity for NK cells and DCs, as we hypothesized. However, other possible, but not mutually exclusive, mechanisms cannot be ruled out; for example, the recruitment of DCs to the tumor sites may be induced by GM-CSF (Fig. 5 B) and/or IL-12 gene delivery (61) and enhanced tumor antigen presentation, which is consistent with the reports by our laboratory and others (63). Second, our previous data demonstrated that IL-12 can activate NK cells, which in conjunction with T-cell activation by 4–1BB ligand or agonistic antibody can induce proliferation of activated T cells (45, 46, 64). In this study, we demonstrated that the combination treatment using gene delivery of GM-CSF, IL-12, and 4–1BB costimulation significantly increased the NK cell number, NK cytotoxicity, and tumor-specific T-cell responses. These effects may result from the reciprocal interaction between DCs and NK cells. Mature DCs can activate IL-12-activated NK cells (65), and NK cells may amplify DC responses through direct and indirect interaction (48, 49, 50). Third, anti-4–1BB can activate GM-CSF- and IL-12-activated DCs and may promote their final maturation.1 These matured DCs prime naive T cells more efficiently, resulting in stronger and more persistent tumor-specific CTL responses and a higher frequency of IFN-γ-producing T cells in tumor-bearing mice treated with the combination of ADV/mGM-CSF, ADV/mIL-12, and anti-4–1BB.\n\nIt has been suggested that elimination of Gr-1+ immature myeloid cells in vivo could be a key step to increasing the efficiency of antitumor vaccines because treatment of immunocompetent mice with anti-Gr-1 mAbs reduced the growth of a variety of UV light-induced tumors (66). On the basis of our findings in this study, inducing the differentiation of Gr-1+ immature myeloid cells in vivo is a more efficient way to not only eliminate suppressive activities by immature myeloid cells but also enhance antitumor immune responses.\n\nIn conclusion, our results suggest that intratumoral delivery of GM-CSF and IL-12 genes in combination with 4–1BB costimulation may offer a new strategy to reverse the immune suppression associated with advanced tumors and improve therapeutic efficacy in hosts with a large tumor burden.\n\n1\n\nGabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer.\n\nClin. Cancer Res.\n\n,\n\n3\n\n:\n\n483\n\n-490,\n\n1997\n\n.\n\n2\n\nMohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X. N., Isnardon D., Sainty D., Olive D., Gaugler B. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment.\n\nBlood\n\n,\n\n98\n\n:\n\n3750\n\n-3756,\n\n2001\n\n.\n\n3\n\nNestle F. O., Burg G., Fah J., Wrone-Smith T., Nickoloff B. J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells.\n\nAm. J. Pathol.\n\n,\n\n150\n\n:\n\n641\n\n-651,\n\n1997\n\n.\n\n4\n\nMedzhitov R., Janeway C., Jr. Innate immune recognition: mechanisms and pathways.\n\nImmunol. Rev.\n\n,\n\n173\n\n:\n\n89\n\n-97,\n\n2000\n\n.\n\n5\n\nFuchs E. J., Matzinger P. Is cancer dangerous to the immune system?.\n\nSemin. Immunol.\n\n,\n\n8\n\n:\n\n271\n\n-280,\n\n1996\n\n.\n\n6\n\nKiertscher S. M., Luo J., Dubinett S. M., Roth M. D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells.\n\nJ. Immunol.\n\n,\n\n164\n\n:\n\n1269\n\n-1276,\n\n2000\n\n.\n\n7\n\nChaux P., Moutet M., Faivre J., Martin F., Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.\n\nLab. Invest.\n\n,\n\n74\n\n:\n\n975\n\n-983,\n\n1996\n\n.\n\n8\n\nEnk A. H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.\n\nInt. J. Cancer\n\n,\n\n73\n\n:\n\n309\n\n-316,\n\n1997\n\n.\n\n9\n\nPirtskhalaishvili G., Shurin G. V., Esche C., Cai Q., Salup R. R., Bykovskaia S. N., Lotze M. T., Shurin M. R. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.\n\nBr. J. Cancer\n\n,\n\n83\n\n:\n\n506\n\n-513,\n\n2000\n\n.\n\n10\n\nEsche C., Gambotto A., Satoh Y., Gerein V., Robbins P. D., Watkins S. C., Lotze M. T., Shurin M. R. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth.\n\nEur. J. Immunol.\n\n,\n\n29\n\n:\n\n2148\n\n-2155,\n\n1999\n\n.\n\n11\n\nZou W., Machelon V., Coulomb-L’Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D. T., Galanaud P., Capron F., Emilie D., Curiel T. J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.\n\nNat. Med.\n\n,\n\n7\n\n:\n\n1339\n\n-1346,\n\n2001\n\n.\n\n12\n\nGabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S., Kavanaugh D., Carbone D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.\n\nNat. Med.\n\n,\n\n2\n\n:\n\n1096\n\n-1103,\n\n1996\n\n.\n\n13\n\nGabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D. P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.\n\nBlood\n\n,\n\n92\n\n:\n\n4150\n\n-4166,\n\n1998\n\n.\n\n14\n\nMenetrier-Caux C., Montmain G., Dieu M. C., Bain C., Favrot M. C., Caux C., Blay J. Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.\n\nBlood\n\n,\n\n92\n\n:\n\n4778\n\n-4791,\n\n1998\n\n.\n\n15\n\nBrown R. D., Pope B., Murray A., Esdale W., Sze D. M., Gibson J., Ho P. J., Hart D., Joshua D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10.\n\nBlood\n\n,\n\n98\n\n:\n\n2992\n\n-2998,\n\n2001\n\n.\n\n16\n\nBronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N. P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.\n\nBlood\n\n,\n\n96\n\n:\n\n3838\n\n-3846,\n\n2000\n\n.\n\n17\n\nGabrilovich D. I., Velders M. P., Sotomayor E. M., Kast W. M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.\n\nJ. Immunol.\n\n,\n\n166\n\n:\n\n5398\n\n-5406,\n\n2001\n\n.\n\n18\n\nPelaez B., Campillo J. A., Lopez-Asenjo J. A., Subiza J. L. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.\n\nJ. Immunol.\n\n,\n\n166\n\n:\n\n6608\n\n-6615,\n\n2001\n\n.\n\n19\n\nBronte V., Chappell D. B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N. P. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.\n\nJ. Immunol.\n\n,\n\n162\n\n:\n\n5728\n\n-5737,\n\n1999\n\n.\n\n20\n\nAlmand B., Clark J. I., Nikitina E., van Beynen J., English N. R., Knight S. C., Carbone D. P., Gabrilovich D. I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.\n\nJ. Immunol.\n\n,\n\n166\n\n:\n\n678\n\n-689,\n\n2001\n\n.\n\n21\n\nCauley L. S., Miller E. E., Yen M., Swain S. L. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-γ.\n\nJ. Immunol.\n\n,\n\n165\n\n:\n\n6056\n\n-6066,\n\n2000\n\n.\n\n22\n\nTerrazas L. I., Walsh K. L., Piskorska D., McGuire E., Harn D. A., Jr. The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections.\n\nJ. Immunol.\n\n,\n\n167\n\n:\n\n5294\n\n-5303,\n\n2001\n\n.\n\n23\n\nJohnson B. D., Hanke C. A., Becker E. E., Truitt R. L. Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro.\n\nCell Immunol.\n\n,\n\n189\n\n:\n\n149\n\n-159,\n\n1998\n\n.\n\n24\n\nSluyter R., Halliday G. M. Enhanced tumor growth in UV-irradiated skin is associated with an influx of inflammatory cells into the epidermis.\n\nCarcinogenesis (Lond.)\n\n,\n\n21\n\n:\n\n1801\n\n-1807,\n\n2000\n\n.\n\n25\n\nAngulo I., Rullas J., Campillo J. A., Obregon E., Heath A., Howard M., Munoz-Fernandez M. A., Subiza J. L. Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-γ stimulation through a mechanism dependent on endogenous TNF-α and IL-1α.\n\nEur. J. Immunol.\n\n,\n\n30\n\n:\n\n1263\n\n-1271,\n\n2000\n\n.\n\n26\n\nKusmartsev S. A., Li Y., Chen S. H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.\n\nJ. Immunol.\n\n,\n\n165\n\n:\n\n779\n\n-785,\n\n2000\n\n.\n\n27\n\nHanada K., Tsunoda R., Hamada H. GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity.\n\nJ. Leukoc. Biol.\n\n,\n\n60\n\n:\n\n181\n\n-190,\n\n1996\n\n.\n\n28\n\nKielian T., Nagai E., Ikubo A., Rasmussen C. A., Suzuki T. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1α and accumulation of dendritic cells at vaccination sites in vivo.\n\nCancer Immunol. Immunother.\n\n,\n\n48\n\n:\n\n123\n\n-131,\n\n1999\n\n.\n\n29\n\nMach N., Gillessen S., Wilson S. B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.\n\nCancer Res.\n\n,\n\n60\n\n:\n\n3239\n\n-3246,\n\n2000\n\n.\n\n30\n\nDranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.\n\nProc. Natl. Acad. Sci. USA\n\n,\n\n90\n\n:\n\n3539\n\n-3543,\n\n1993\n\n.\n\n31\n\nChiodoni C., Paglia P., Stoppacciaro A., Rodolfo M., Parenza M., Colombo M. P. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.\n\nJ. Exp. Med.\n\n,\n\n190\n\n:\n\n125\n\n-133,\n\n1999\n\n.\n\n32\n\nWang J., Snider D. P., Hewlett B. R., Lukacs N. W., Gauldie J., Liang H., Xing Z. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung.\n\nBlood\n\n,\n\n95\n\n:\n\n2337\n\n-2345,\n\n2000\n\n.\n\n33\n\nSteinman R. M. The dendritic cell system and its role in immunogenicity.\n\nAnnu. Rev. Immunol.\n\n,\n\n9\n\n:\n\n271\n\n-296,\n\n1991\n\n.\n\n34\n\nCuriel-Lewandrowski C., Mahnke K., Labeur M., Roters B., Schmidt W., Granstein R. D., Luger T. A., Schwarz T., Grabbe S. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.\n\nJ. Immunol.\n\n,\n\n163\n\n:\n\n174\n\n-183,\n\n1999\n\n.\n\n35\n\nPham-Nguyen K. B., Yang W., Saxena R., Thung S. N., Woo S. L., Chen S. H. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma.\n\nInt. J. Cancer\n\n,\n\n81\n\n:\n\n813\n\n-819,\n\n1999\n\n.\n\n36\n\nTahara H., Zitvogel L., Storkus W. J., Robbins P. D., Lotze M. T. Murine models of cancer cytokine gene therapy using interleukin-12.\n\nAnn. N. Y. Acad. Sci.\n\n,\n\n795\n\n:\n\n275\n\n-283,\n\n1996\n\n.\n\n37\n\nZitvogel L., Robbins P. D., Storkus W. J., Clarke M. R., Maeurer M. J., Campbell R. L., Davis C. G., Tahara H., Schreiber R. D., Lotze M. T. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.\n\nEur. J. Immunol.\n\n,\n\n26\n\n:\n\n1335\n\n-1341,\n\n1996\n\n.\n\n38\n\nSaudemont A., Buffenoir G., Denys A., Desreumaux P., Jouy N., Hetuin D., Bauters F., Fenaux P., Quesnel B. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia.\n\nLeukemia (Baltimore)\n\n,\n\n16\n\n:\n\n1637\n\n-1644,\n\n2002\n\n.\n\n39\n\nPoligone B., Weaver D. J., Jr., Sen P., Baldwin A. S., Jr., Tisch R. Elevated NF-κB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function.\n\nJ. Immunol.\n\n,\n\n168\n\n:\n\n188\n\n-196,\n\n2002\n\n.\n\n40\n\nShuford W. W., Klussman K., Tritchler D. D., Loo D. T., Chalupny J., Siadak A. W., Brown T. J., Emswiler J., Raecho H., Larsen C. P., Pearson T. C., Ledbetter J. A., Aruffo A., Mittler R. S. 4–1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.\n\nJ. Exp. Med.\n\n,\n\n186\n\n:\n\n47\n\n-55,\n\n1997\n\n.\n\n41\n\nVinay D. S., Kwon B. S. Role of 4–1BB in immune responses.\n\nSemin. Immunol.\n\n,\n\n10\n\n:\n\n481\n\n-489,\n\n1998\n\n.\n\n42\n\nHalstead E. S., Mueller Y. M., Altman J. D., Katsikis P. D. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses.\n\nNat. Immunol.\n\n,\n\n3\n\n:\n\n536\n\n-541,\n\n2002\n\n.\n\n43\n\nWilcox R. A., Chapoval A. I., Gorski K. S., Otsuji M., Shin T., Flies D. B., Tamada K., Mittler R. S., Tsuchiya H., Pardoll D. M., Chen L. Cutting edge: expression of functional CD137 receptor by dendritic cells.\n\nJ. Immunol.\n\n,\n\n168\n\n:\n\n4262\n\n-4267,\n\n2002\n\n.\n\n44\n\nFutagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H., Okumura K. Expression and function of 4–1BB and 4–1BB ligand on murine dendritic cells.\n\nInt. Immunol.\n\n,\n\n14\n\n:\n\n275\n\n-286,\n\n2002\n\n.\n\n45\n\nCaruso M., Pham-Nguyen K., Kwong Y. L., Xu B., Kosai K. I., Finegold M., Woo S. L., Chen S. H. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.\n\nProc. Natl. Acad. Sci. USA\n\n,\n\n93\n\n:\n\n11302\n\n-11306,\n\n1996\n\n.\n\n46\n\nChen S. H., Pham-Nguyen K. B., Martinet O., Huang Y., Yang W., Thung S. N., Chen L., Mittler R., Woo S. L. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4–1BB costimulation.\n\nMol. Ther.\n\n,\n\n2\n\n:\n\n39\n\n-46,\n\n2000\n\n.\n\n47\n\nPan P.-Y., Zang Y., Weber K., Meseck M. L., Chen S.-H. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.\n\nMol. Ther.\n\n,\n\n6\n\n:\n\n528\n\n-536,\n\n2002\n\n.\n\n48\n\nPiccioli D., Sbrana S., Melandri E., Valiante N. M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells.\n\nJ. Exp. Med.\n\n,\n\n195\n\n:\n\n335\n\n-341,\n\n2002\n\n.\n\n49\n\nOsada T., Nagawa H., Kitayama J., Tsuno N. H., Ishihara S., Takamizawa M., Shibata Y. Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function.\n\nCell Immunol.\n\n,\n\n213\n\n:\n\n14\n\n-23,\n\n2001\n\n.\n\n50\n\nFerlazzo G., Tsang M. L., Moretta L., Melioli G., Steinman R. M., Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.\n\nJ. Exp. Med.\n\n,\n\n195\n\n:\n\n343\n\n-351,\n\n2002\n\n.\n\n51\n\nHernandez J., Aung S., Marquardt K., Sherman L. A. Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens.\n\nJ. Exp. Med.\n\n,\n\n196\n\n:\n\n323\n\n-333,\n\n2002\n\n.\n\n52\n\nKirberg J., Baron A., Jakob S., Rolink A., Karjalainen K., von Boehmer H. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.\n\nJ. Exp. Med.\n\n,\n\n180\n\n:\n\n25\n\n-34,\n\n1994\n\n.\n\n53\n\nCorbett T. H., Griswold D. P., Jr., Roberts B. J., Peckham J. C., Schabel F. M., Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.\n\nCancer Res.\n\n,\n\n35\n\n:\n\n2434\n\n-2439,\n\n1975\n\n.\n\n54\n\nChen S. H., Kosai K., Xu B., Pham-Nguyen K., Contant C., Finegold M. J., Woo S. L. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival.\n\nCancer Res.\n\n,\n\n56\n\n:\n\n3758\n\n-3762,\n\n1996\n\n.\n\n55\n\nFernando G. J., Khammanivong V., Leggatt G. R., Liu W. J., Frazer I. H. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation.\n\nEur. J. Immunol.\n\n,\n\n32\n\n:\n\n1541\n\n-1549,\n\n2002\n\n.\n\n56\n\nLutz M. B., Kukutsch N., Ogilvie A. L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.\n\nJ. Immunol. Methods\n\n,\n\n223\n\n:\n\n77\n\n-92,\n\n1999\n\n.\n\n57\n\nKusmartsev S., Gabrilovich D. I. Immature myeloid cells and cancer-associated immune suppression.\n\nCancer Immunol. Immunother\n\n,\n\n51\n\n:\n\n293\n\n-298,\n\n2002\n\n.\n\n58\n\nSugiura K., Ikehara S., Inaba M., Haraguchi S., Ogata H., Sardina E. E., Sugawara M., Ohta Y., Good R. A. Enrichment of murine bone marrow natural suppressor activity in the fraction of hematopoietic progenitors with interleukin 3 receptor-associated antigen.\n\nExp. Hematol.\n\n,\n\n20\n\n:\n\n256\n\n-263,\n\n1992\n\n.\n\n59\n\ndel Hoyo G. M., Martin P., Vargas H. H., Ruiz S., Arias C. F., Ardavin C. Characterization of a common precursor population for dendritic cells.\n\nNature (Lond.)\n\n,\n\n415\n\n:\n\n1043\n\n-1047,\n\n2002\n\n.\n\n60\n\nFerrero I., Held W., Wilson A., Tacchini-Cottier F., Radtke F., MacDonald H. R. Mouse CD11c(+) B220(+) Gr1(+) plasmacytoid dendritic cells develop independently of the T-cell lineage.\n\nBlood\n\n,\n\n100\n\n:\n\n2852\n\n-2857,\n\n2002\n\n.\n\n61\n\nGilliet M., Boonstra A., Paturel C., Antonenko S., Xu X. L., Trinchieri G., O’Garra A., Liu Y. J. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor.\n\nJ. Exp. Med.\n\n,\n\n195\n\n:\n\n953\n\n-958,\n\n2002\n\n.\n\n62\n\nNakano H., Yanagita M., Gunn M. D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells.\n\nJ. Exp. Med.\n\n,\n\n194\n\n:\n\n1171\n\n-1178,\n\n2001\n\n.\n\n63\n\nBasak S. K., Harui A., Stolina M., Sharma S., Mitani K., Dubinett S. M., Roth M. D. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4.\n\nBlood\n\n,\n\n99\n\n:\n\n2869\n\n-2879,\n\n2002\n\n.\n\n64\n\nMartinet O., Ermekova V., Qiao J. Q., Sauter B., Mandeli J., Chen L., Chen S. H. Immunomodulatory gene therapy with interleukin 12 and 4–1BB ligand: long-term remission of liver metastases in a mouse model.\n\nJ. Natl. Cancer Inst.\n\n,\n\n92\n\n:\n\n931\n\n-936,\n\n2000\n\n.\n\n65\n\nFernandez N. C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.\n\nNat. Med.\n\n,\n\n5\n\n:\n\n405\n\n-411,\n\n1999\n\n.\n\n66\n\nSeung L. P., Rowley D. A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.\n\nProc. Natl. Acad. Sci. USA\n\n,\n\n92\n\n:\n\n6254\n\n-6258,\n\n1995\n\n."
    }
}